Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Price Fixation: NPPA...

    Price Fixation: NPPA revises ceiling prices of 16 drugs including Condoms ; Details

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-02T12:34:37+05:30  |  Updated On 16 Aug 2021 2:25 PM IST

    New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of 16 drug formulations used for treating various ailments, including Acetyl Salicylic Acid, Calcium Carbonate tablets, Condoms, Ethyl Alcohol 70% Solution, Rifampicin and others.


    Accounting for inflation, the ceiling prices have been increased by 4.2662%. The ceiling prices are applicable with effect from 01.4.2019


    Some of the formulations whose price has been revised by the NPPA are Acetyl Salicylic Acid, Calcium Carbonate used as an antacid to relieve heartburn, acid indigestion, and upset stomach; Condoms, Ethyl Alcohol 70% Solution, Rifampicin are other formulations whose prices have been revised. The details of the medicines reads;


    Also Read: NPPA revises price of Coronary Stents; Check out Details







































































































































































    Sl NoMedicinesDosage form and StrengthUnitCeiling price (wef 1.4.2019 with WPI @

    4.2662%)
    Existing S.O. No. & Date
    (1)(2)(3)(4)(5)6(a)6(b)
    1Acetyl Salicylic AcidTablet 300mg1 Tablet0.221491462(E)02.04.2018
    2Calcium carbonateTablet 250 mg1 Tablet1.911462(E)02.04.2018
    3Calcium carbonateTablet 500 mg1 Tablet1.901462(E)02.04.2018
    4Condoms1 Condom8.931462(E)02.04.2018
    5DapsoneTablet 50 mg1 Tablet0.230951462(E)02.04.2018
    6DaunorubicinInjection 20 mgEach Pack417.841462(E)02.04.2018
    7Ethyl Alcohol 70% Solution1 ML0.561462(E)02.04.2018
    8EtoposideCapsules 100 mg1 Capsule59.251462(E)02.04.2018
    9Framycetin SulphateCream 0.50%1 GM0.851462(E)02.04.2018
    10Gentian Violet

    Paint
    1%1 ML0.063951462(E)02.04.2018
    11IsoniazidSyrup 100 mg/5ml1 ML0.252951462(E)02.04.2018
    12Medroxy Progesterone AcetateTablet 5mg1 Tablet2.921462(E)02.04.2018
    13Oral Poliomyelitis

    vaccine (LA)
    Solution1 ML118.021462(E)02.04.2018
    14PraziquantelTablet 600 mg1 Tablet28.211462(E)02.04.2018
    15RifampicinTablet 450mg1 Tablet4.341462(E)02.04.2018
    16Sodium NitriteInjection 30mg/ml1 ML21.111462(E)02.04.2018

    The notice further adds;




    • All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services taxes as applicable, if any.

    • All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 4.2662% for year 2018 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO,

    • The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said

    • The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and

    • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the

    • Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,

    • The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of

    • The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,

    • Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)


    Also Read: NPPA revises ceiling prices of 14 drug formulations including Injections, Inhalators; Details

    AsprinCalcium Carbonate tabletscondomdrug formulationdrug pricehealthhealth carehealth care newsHealthcarelatest price fixmedicalmedical newsmedicineMedicine MRPmedicinesNational Pharmaceutical Pricing AuthorityNPPApharmapharma newspharma news indiapolicy news

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok